APAC In Situ Hybridization Market

APAC In Situ Hybridization Market by Products (Consumables, Instruments, Software), Technology (DNA FISH, RNA FISH, PNA FISH, CISH), Application (Cancer, Immunology, Neuroscience, Cytology), End User (Hospital, Pharma, Biotech, CROs) - Forecast to 2027

Report Code: BT 8537 Jan, 2023, by marketsandmarkets.com

[158 Pages Reports] The APAC in situ hybridization market size is Projected to grow from USD 363 million in 2022 to reach USD 744 million by 2027, at a CAGR of 15.4% during the forecast period. In developed countries, high-quality molecular diagnostic tests are readily available. However, in developing countries, the cost of these diagnostic technologies is very high, which often makes them unaffordable for a large part of the population. Moreover, the lack of a commercial market for diagnostic procedures has resulted in the availability of a small number of diagnostic tests in developing countries. As a result, emerging markets such as India, China, and South Korea offer significant growth opportunities for MDx-based technologies (including ISH) owing to the rising geriatric population, the growing prevalence of infectious diseases and various types of cancers, the improving healthcare infrastructure, and increasing investments by respective government bodies and leading players in these countries.

Attractive Opportunities in the in Situ Hybridization Market

IoT in Smart Cities Market

To know about the assumptions considered for the study, Request for Free Sample Report

Global In Situ Hybridization Market Dynamics

DRIVER: Rising incidence of genetic disorders and cancer

Clinical trials pertaining to genetic disorders increased most significantly in the Asia Pacific region. The number of trials conducted increased by 184% between 2010 and 2020. Japan accounted for the largest share, with 28.4% of all trials in the region taking place in Japan in 2020. Australia (25%) and China (21.6%) accounted for the second- and third-largest shares of the overall number of ongoing trials in the region. Moreover, Southeast Asians are more likely to have genetic disorders, according to a study led by co-senior authors Dr. Kumaraswamy Thangaraj of the CSIR-Centre for Cellular and Molecular Biology (CCMB) and Dr. David Reich of the Broad Institute of MIT and Harvard, Cambridge, US, in collaboration with other institutes.

CHALLENGES: Shortage of skilled professionals

In Situ hybridization requires high technical know-how. For instance, understanding of the molecular information of a chromosome or a gene is crucial for conducting ISH tests. Moreover, there is a reluctcance to move from tradional approaches to IT-based approaches such as in situ hybridization. Thus, the shortage of skilled professionals for conducting in situ hybridization tests will hinder the market growth over the forecast period.

The consumables accounted for the largest share of the in situ hybridization market in 2021.

The in situ hybridization market is segmented into consumables, instruments, and software based on product. In 2021, the ISH consumables segment accounted for the largest share of the in situ hybridization market. The growing government and private funding in life sciences and cancer research, the increasing number of reagent rental agreements, and the application of innovative technologies and methodologies in the fields of tissue and in vitro diagnostics are expected to drive the growth of the consumables market during the forecast period.

The DNA FISH technology segment dominated the fluorescent in situ hybridization market in 2021.

Based on the technology, the in situ hybridization market is FISH (fluorescent in situ hybridization) and CISH (chromogenic in situ hybridization). The FISH segment is further categorized into DNA FISH, RNA FISH, and PNA FISH. In 2021, the FISH segment dominated the APAC in situ hybridization market with the highest revenue share as FISH is better for data analysis as FISh offers better visuals on software.

In 2021, hospitals & diagnostic laboratories generated the highest revenue in the in situ hybridization market.

Based on the end user, the Asia Pacific in situ hybridization market is segmented into hospital & diagnostic laboratories, academic and research institutes, CROs, and pharmaceutical & biotechnology companies. In 2021, the hospital & diagnostic laboratories generated the second highest revenue in the APAC in situ hybridization market.The growing patient population, increase in Medicare reimbursements for clinical tests performed in hospitals, and the emergence of advanced diagnostic tests are some of the key factors driving the growth of this end-user segment.

Japan was the largest market for Asia Pacific in situ hybridization in 2021.

Companies in Japan are increasingly focusing on revolutionizing the field of precision oncology and personalized medicine with the integration of genetics and proteomics diagnosis. Several collaborations have been observed in the country, which support the research industry in Japan. This trend is expected to continue in the coming years and contribute to market growth in Japan.

To curb the growing incidence of chronic diseases, the Japanese government has been taking initiatives for targeted treatments & personalized therapies, such as the establishment of the Center for Cancer Genomics and Advanced Therapeutics. This initiative is the focal point through which the government aims to aggregate and manage public information on genomic medicine. Efforts like these will also favor market growth in the country.

IoT in Smart Cities Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key Market Players

Prominent players in the in situ hybridization market include Abbott Laboratories (US), Thermo Fisher Scientific (US), Danaher Corporation (US), Merck (Germany), F. Hoffmann-La Roche (Switzerland), BioView (Israel), Agilent Technologies (US), Biocare Medical (US), Bio-Techne Corporation (US), QIAGEN (Germany), PerkinElmer (US), Enzo Biochem (US), Bio-Rad Laboratories (US), Abnova Corporation (Taiwan), BioGenex Laboratories (US), OpGen (US), Bio SB (US), Abcam (UK), Zytomed (Germany), 10x Genomics Inc. (US), and NeoGenomics Laboratories (US).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2020–2027

Base year considered

2021

Forecast period

2022–2027

Forecast units

Value (USD)

Segments covered

Product, Technology, Application, End User and Country

Countries covered

Japan, China, India, South Korea, Taiwan, Singapore, Australia, New Zealand, and Rest of Asia Pacific.

Companies covered

Abbott Laboratories (US), Thermo Fisher Scientific (US), Danaher Corporation (US), Merck (Germany), F. Hoffmann-La Roche (Switzerland), BioView (Israel), Agilent Technologies (US), Biocare Medical (US), Bio-Techne Corporation (US), QIAGEN (Germany), PerkinElmer (US), Enzo Biochem (US), Bio-Rad Laboratories (US), Abnova Corporation (Taiwan), BioGenex Laboratories (US), OpGen (US), Bio SB (US), Abcam (UK), Zytomed (Germany), 10x Genomics Inc. (US), and NeoGenomics Laboratories (US).

This report categorizes the Asia Pacific in situ hybridization market into the following segments:

In situ hybridization Market, by Product
  • Consumables
  • Kits & Reagents
  • Probes
  • Accessories
  • Instruments
  • Software
Asia Pacific In situ hybridization Market, by Technology
  • FISH
  • DNA FISH
  • RNA FISH
  • PNA FISH
  • CISH
Asia Pacific In situ hybridization Market, by Application
Asia Pacific In situ hybridization Market, by End User
  • Hospitals and Diagnostic Laboratories
  • Academic and Research Institutes
  • CROs
  • Pharmaceutical and Biotechnology Companies
In situ hybridization Market, by Country
  • Japan
  • China
  • India
  • South Korea
  • Taiwan
  • Singapore
  • Australia
  • New Zealand
  • Rest of Asia Pacific (RoAPAC)

Recent Developments

  • In 2022, RNAscope ISH Detection Kit manufactured by Bio-Techne received CE-IVD approval for the BOND-III platform (Leica Biosystems).
  • In 2021, Applied Spectral Imaging (ASI) and KromaTiD, Inc. entered a strategic commercial partnership granting ASI worldwide rights to market KromaTiD’s proprietary Pinpoint FISH (PPF) probes and assay services.
  • In 2020, Creative Bioarray introduced an advanced FISH probe to detect the 2019 Novel Coronavirus.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 22)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
    1.4 YEARS CONSIDERED 
    1.5 CURRENCY CONSIDERED 
    1.6 LIMITATIONS 
    1.7 STAKEHOLDERS 
    1.8 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 25)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 2 BREAKDOWN OF PRIMARIES: APAC IN SITU HYBRIDIZATION MARKET
    2.2 MARKET ESTIMATION METHODOLOGY 
          FIGURE 3 MARKET SIZE ESTIMATION (COMPANY REVENUE ANALYSIS-BASED ESTIMATION)
          FIGURE 4 APAC IN SITU HYBRIDIZATION MARKET SIZE, 2021 (USD MILLION)
          FIGURE 5 APAC IN SITU HYBRIDIZATION MARKET: FINAL CAGR PROJECTIONS (2022−2027)
          FIGURE 6 APAC IN SITU HYBRIDIZATION MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DEMAND-SIDE DRIVERS, OPPORTUNITIES, AND CHALLENGES
    2.3 MARKET DATA ESTIMATION & TRIANGULATION 
          FIGURE 7 DATA TRIANGULATION METHODOLOGY
    2.4 INDUSTRY INSIGHTS 
    2.5 RESEARCH ASSUMPTIONS 
 
3 EXECUTIVE SUMMARY (Page No. - 31)
    FIGURE 8 APAC IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
    FIGURE 9 APAC IN SITU HYBRIDIZATION MARKET SHARE, BY PRODUCT, 2021
    FIGURE 10 APAC IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    FIGURE 11 APAC FLUORESCENCE IN SITU HYBRIDIZATION MARKET SHARE, BY TYPE, 2021
    FIGURE 12 APAC IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
 
4 PREMIUM INSIGHTS (Page No. - 34)
    4.1 APAC IN SITU HYBRIDIZATION MARKET OVERVIEW 
          FIGURE 13 GROWING FOCUS ON COMPANION DIAGNOSTICS AND INCREASING CANCER INCIDENCE TO FAVOR MARKET GROWTH
    4.2 APAC IN SITU HYBRIDIZATION MARKET, BY END USER, 2021 VS. 2027 (USD MILLION) 
          FIGURE 14 HOSPITAL & DIAGNOSTIC LABORATORIES TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 36)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 15 APAC IN SITU HYBRIDIZATION MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
          TABLE 1 APAC IN SITU HYBRIDIZATION MARKET: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Increasing incidence of genetic disorders and cancer
                                TABLE 2 NEW CASES OF CANCER IN ASIA, 2020 VS. 2025
                                FIGURE 16 HEMOPHILIA OCCURRENCE, BY REGION
                    5.2.1.2 Growing awareness about companion diagnostics
           5.2.2 OPPORTUNITIES
                    5.2.2.1 Untapped markets in developing countries
           5.2.3 CHALLENGES
                    5.2.3.1 Shortage of skilled professionals
    5.3 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 3 APAC IN SITU HYBRIDIZATION MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.3.1 THREAT FROM NEW ENTRANTS
           5.3.2 THREAT FROM SUBSTITUTES
           5.3.3 BARGAINING POWER OF BUYERS
           5.3.4 BARGAINING POWER OF SUPPLIERS
           5.3.5 INTENSITY OF COMPETITIVE RIVALRY
    5.4 SUPPLY CHAIN ANALYSIS 
          FIGURE 17 SUPPLY CHAIN ANALYSIS OF APAC IN SITU HYBRIDIZATION MARKET
    5.5 VALUE CHAIN ANALYSIS 
          FIGURE 18 VALUE CHAIN ANALYSIS OF APAC IN SITU HYBRIDIZATION MARKET
    5.6 ECOSYSTEM ANALYSIS 
          FIGURE 19 ECOSYSTEM ANALYSIS OF APAC IN SITU HYBRIDIZATION MARKET
    5.7 KEY CONFERENCES & EVENTS IN 2022–2023 
          TABLE 4 KEY CONFERENCES & EVENTS, 2022–2023
    5.8 REGULATORY ANALYSIS 
           5.8.1 FDA APPROVALS
           5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 5 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.9 PRICING ANALYSIS 
          TABLE 6 PRICING ANALYSIS OF IN SITU HYBRIDIZATION PRODUCTS
           5.9.1 APAC IN SITU HYBRIDIZATION MARKET: AVERAGE SELLING PRICE TRENDS
                    TABLE 7 PRICING ANALYSIS OF FISH TESTS IN INDIA (2021)
    5.10 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
                    FIGURE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IN SITU HYBRIDIZATION MARKET IN ASIA PACIFIC
           5.10.2 BUYING CRITERIA FOR IN SITU HYBRIDIZATION MARKET IN ASIA PACIFIC
                    FIGURE 21 KEY BUYING CRITERIA FOR END USERS
 
6 APAC IN SITU HYBRIDIZATION MARKET, BY PRODUCT (Page No. - 49)
    6.1 INTRODUCTION 
          TABLE 8 APAC IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
    6.2 CONSUMABLES 
          TABLE 9 APAC IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 10 APAC IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY COUNTRY, 2020–2027 (USD MILLION)
           6.2.1 PROBES
                    6.2.1.1 Growing preference for direct localization of DNA/RNA sequences using probes to drive market
                                TABLE 11 APAC IN SITU HYBRIDIZATION MARKET FOR PROBES, BY COUNTRY, 2020–2027 (USD MILLION)
           6.2.2 KITS & REAGENTS
                    6.2.2.1 Growing focus on companion diagnostics to boost demand
                                TABLE 12 APAC IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
           6.2.3 ACCESSORIES
                    6.2.3.1 Use of accessories for optimal performance of FISH and CISH probes to propel adoption
                                TABLE 13 APAC IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY COUNTRY, 2020–2027 (USD MILLION)
    6.3 INSTRUMENTS 
           6.3.1 RISING NEED FOR AUTOMATED SYSTEMS TO SUPPORT MARKET
                    TABLE 14 APAC IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.4 SOFTWARE 
           6.4.1 GROWING DEMAND FOR HIGH-SPEED SAMPLE DATA ANALYSIS TO DRIVE MARKET
                    TABLE 15 APAC IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
 
7 APAC IN SITU HYBRIDIZATION MARKET, BY APPLICATION (Page No. - 56)
    7.1 INTRODUCTION 
          TABLE 16 APAC IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
    7.2 CANCER DIAGNOSTICS 
           7.2.1 GROWING IMPORTANCE OF COMPANION DIAGNOSTICS TO DRIVE MARKET
                    TABLE 17 APAC IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.3 CYTOLOGY 
           7.3.1 GROWING DEMAND FOR FISH FOR DETECTION OF CHROMOSOMAL ABNORMALITIES TO SUPPORT MARKET
                    TABLE 18 APAC IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
    7.4 INFECTIOUS DISEASE DIAGNOSTICS 
           7.4.1 NEED FOR HIGH SENSITIVITY AND SPECIFICITY IN INFECTIOUS DISEASE DIAGNOSIS TO AID GROWTH
                    TABLE 19 APAC IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.5 NEUROSCIENCE 
           7.5.1 RISING BURDEN OF NEUROLOGICAL DISORDERS TO BOOST R&D ACTIVITIES
                    TABLE 20 APAC IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020–2027 (USD MILLION)
    7.6 IMMUNOLOGY 
           7.6.1 RISING INCIDENCE OF AUTOIMMUNE DISEASES TO DRIVE GROWTH
                    TABLE 21 APAC IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
 
8 APAC IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY (Page No. - 63)
    8.1 INTRODUCTION 
          TABLE 22 APAC IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
    8.2 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 
          TABLE 23 APAC FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 24 APAC FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           8.2.1 DNA FLUORESCENCE IN SITU HYBRIDIZATION
                    8.2.1.1 Need to ensure stability of genetic material to drive market
                                TABLE 25 APAC DNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           8.2.2 RNA FLUORESCENCE IN SITU HYBRIDIZATION
                    8.2.2.1 Increasing biomedical research to support market growth
                                TABLE 26 APAC RNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           8.2.3 PNA FLUORESCENCE IN SITU HYBRIDIZATION
                    8.2.3.1 Increased applications in infectious disease diagnosis to boost market
                                TABLE 27 APAC PNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    8.3 CHROMOGENIC IN SITU HYBRIDIZATION (CISH) 
           8.3.1 COST-EFFECTIVENESS OF CISH OVER FISH TO BOOST MARKET GROWTH
                    TABLE 28 APAC CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
 
9 APAC IN SITU HYBRIDIZATION MARKET, BY END USER (Page No. - 70)
    9.1 INTRODUCTION 
          TABLE 29 APAC IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.2 HOSPITAL & DIAGNOSTIC LABORATORIES 
           9.2.1 GROWING VOLUME OF MOLECULAR TESTS TO DRIVE MARKET
                    TABLE 30 APAC IN SITU HYBRIDIZATION MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
    9.3 ACADEMIC & RESEARCH INSTITUTES 
           9.3.1 GROWING RESEARCH ON CHROMOSOMAL ABNORMALITIES TO SUPPORT MARKET
                    TABLE 31 APAC IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
    9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
           9.4.1 NEED TO DEVELOP PRECISION TREATMENTS TO DRIVE DEMAND FOR ISH
                    TABLE 32 APAC IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
    9.5 CONTRACT RESEARCH ORGANIZATIONS 
           9.5.1 INCREASING OUTSOURCING OF RESEARCH ACTIVITIES TO BOOST MARKET
                    TABLE 33 APAC IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
 
10 APAC IN SITU HYBRIDIZATION MARKET, BY COUNTRY (Page No. - 76)
     10.1 INTRODUCTION 
            FIGURE 22 APAC IN SITU HYBRIDIZATION MARKET SNAPSHOT
            TABLE 34 APAC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             10.1.1 JAPAN
                        10.1.1.1 Growing focus on personalized diagnostics to support market growth
                                      TABLE 35 JAPAN: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 36 JAPAN: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 37 JAPAN: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
                                      TABLE 38 JAPAN: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 39 JAPAN: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 40 JAPAN: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             10.1.2 CHINA
                        10.1.2.1 China to register highest CAGR during forecast period
                                      TABLE 41 CHINA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 42 CHINA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 43 CHINA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
                                      TABLE 44 CHINA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 45 CHINA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 46 CHINA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             10.1.3 INDIA
                        10.1.3.1 Collaborations between hospitals and diagnostic labs to propel market growth in India
                                      TABLE 47 INDIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 48 INDIA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 49 INDIA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
                                      TABLE 50 INDIA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 51 INDIA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 52 INDIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             10.1.4 SOUTH KOREA
                        10.1.4.1 Robust healthcare infrastructure to boost growth
                                      TABLE 53 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 54 SOUTH KOREA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 55 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
                                      TABLE 56 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 57 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 58 SOUTH KOREA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             10.1.5 TAIWAN
                        10.1.5.1 Improving cancer research and care to propel demand for ISH
                                      TABLE 59 TAIWAN: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 60 TAIWAN: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 61 TAIWAN: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
                                      TABLE 62 TAIWAN: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 63 TAIWAN: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 64 TAIWAN: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             10.1.6 SINGAPORE
                        10.1.6.1 Government initiatives to make cancer treatment more affordable to contribute to growth
                                      TABLE 65 SINGAPORE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 66 SINGAPORE: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 67 SINGAPORE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
                                      TABLE 68 SINGAPORE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 69 SINGAPORE: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 70 SINGAPORE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             10.1.7 AUSTRALIA
                        10.1.7.1 Increasing public-private investments in cancer research to boost demand
                                      TABLE 71 AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 72 AUSTRALIA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 73 AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
                                      TABLE 74 AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 75 AUSTRALIA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 76 AUSTRALIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             10.1.8 NEW ZEALAND
                        10.1.8.1 Rising cases of cancer to propel growth
                                      TABLE 77 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 78 NEW ZEALAND: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 79 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
                                      TABLE 80 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 81 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 82 NEW ZEALAND: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             10.1.9 REST OF ASIA PACIFIC
                        TABLE 83 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 84 REST OF ASIA PACIFIC: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 85 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020–2027 (USD MILLION)
                        TABLE 86 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 87 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 88 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
 
11 COMPETITIVE LANDSCAPE (Page No. - 101)
     11.1 INTRODUCTION 
     11.2 RIGHT-TO-WIN STRATEGIES ADOPTED BY KEY PLAYERS 
             TABLE 89 APAC IN SITU HYBRIDIZATION MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
     11.3 MARKET SHARE ANALYSIS 
             FIGURE 23 APAC IN SITU HYBRIDIZATION MARKET SHARE ANALYSIS (2021)
     11.4 REVENUE SHARE ANALYSIS 
             FIGURE 24 REVENUE ANALYSIS OF KEY COMPANIES (2019−2021)
     11.5 COMPANY EVALUATION QUADRANT 
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
                        FIGURE 25 APAC IN SITU HYBRIDIZATION MARKET: COMPANY EVALUATION MATRIX (2021)
     11.6 COMPETITIVE SCENARIO AND TRENDS 
             11.6.1 PRODUCT LAUNCHES
                        TABLE 90 APAC IN SITU HYBRIDIZATION MARKET: PRODUCT LAUNCHES, 2019–2022
             11.6.2 DEALS
                        TABLE 91 APAC IN SITU HYBRIDIZATION MARKET: DEALS, 2019–2022
 
12 COMPANY PROFILES (Page No. - 108)
     12.1 KEY COMPANIES 
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
             12.1.1 ABBOTT LABORATORIES
                        TABLE 92 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 26 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
             12.1.2 F. HOFFMANN-LA ROCHE AG
                        TABLE 93 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
                        FIGURE 27 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021)
             12.1.3 THERMO FISHER SCIENTIFIC, INC.
                        TABLE 94 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                        FIGURE 28 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
             12.1.4 DANAHER CORPORATION
                        TABLE 95 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 29 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
             12.1.5 AGILENT TECHNOLOGIES, INC.
                        TABLE 96 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
                        FIGURE 30 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021)
             12.1.6 BIOCARE MEDICAL
                        TABLE 97 BIOCARE MEDICAL: BUSINESS OVERVIEW
             12.1.7 BIO-TECHNE CORPORATION
                        TABLE 98 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW
                        FIGURE 31 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2021)
             12.1.8 QIAGEN N.V.
                        TABLE 99 QIAGEN N.V.: BUSINESS OVERVIEW
                        FIGURE 32 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
             12.1.9 MERCK KGAA
                        TABLE 100 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2021)
             12.1.10 PERKINELMER
                        TABLE 101 PERKINELMER: BUSINESS OVERVIEW
                        FIGURE 34 PERKINELMER: COMPANY SNAPSHOT (2021)
             12.1.11 ENZO BIOCHEM
                        TABLE 102 ENZO BIOCHEM: BUSINESS OVERVIEW
                        FIGURE 35 ENZO BIOCHEM: COMPANY SNAPSHOT (2021)
             12.1.12 BIO-RAD LABORATORIES
                        TABLE 103 BIO-RAD LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 36 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021)
             12.1.13 ABNOVA CORPORATION
                        TABLE 104 ABNOVA CORPORATION: BUSINESS OVERVIEW
             12.1.14 BIOGENEX LABORATORIES
                        TABLE 105 BIOGENEX LABORATORIES: BUSINESS OVERVIEW
             12.1.15 OPGEN INC.
                        TABLE 106 OPGEN INC.: BUSINESS OVERVIEW
                        FIGURE 37 OPGEN INC.: COMPANY SNAPSHOT (2021)
             12.1.16 BIO SB
                        TABLE 107 BIO SB: BUSINESS OVERVIEW
             12.1.17 ABCAM
                        TABLE 108 ABCAM: BUSINESS OVERVIEW
                        FIGURE 38 ABCAM: COMPANY SNAPSHOT (2021)
             12.1.18 ZYTOMED SYSTEMS GMBH
                        TABLE 109 ZYTOMED SYSTEMS GMBH: BUSINESS OVERVIEW
             12.1.19 NEOGENOMICS LABORATORIES
                        TABLE 110 NEOGENOMICS LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 39 NEOGENOMICS LABORATORIES: COMPANY SNAPSHOT (2021)
             12.1.20 BIOVIEW
                        TABLE 111 BIOVIEW: BUSINESS OVERVIEW
                        FIGURE 40 BIOVIEW: COMPANY SNAPSHOT (2021)
             12.1.21 10X GENOMICS
                        TABLE 112 10X GENOMICS: BUSINESS OVERVIEW
                        FIGURE 41 10X GENOMICS: COMPANY SNAPSHOT (2021)
 
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
 
13 APPENDIX (Page No. - 153)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the Asia Pacific in situ hybridization market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the in situ hybridization market. The secondary sources used for this study include Some of the key secondary sources referred to for this study include publications from government sources World Health Organization (WHO), Organization for Economic Co-operation and Development (OECD), GLOBOCAN, World Bank, World Cancer Research Fund, Centers for Disease Control and Prevention (CDC), American Cancer Society (ACS), American Association for Clinical Chemistry, US Food and Drug Administration (FDA). These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

IoT in Smart Cities Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the in situ hybridization market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the in situ hybridization business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the Asia Pacific in situ hybridization market based on product, technology, application, end user, and country
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, challenges, and opportunities)
  • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the Asia Pacific in situ hybridization market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to eight key countries, namely, Japan, China, India, South Korea, Taiwan, Singapore, Australia, New Zealand, and Rest of Asia Pacific.
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, product launches, and expansions in the Asia Pacific in situ hybridization market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Company Information

  • An additional five company profiles

Global Analysis

  • Breakdown of Market into North America, Europe, Asia Pacific, and Rest of the World.
Report Code
BT 8537
Published ON
Jan, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the APAC In Situ Hybridization Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback